#1 Clinical Trials Search in Europe

Isatuximab

Isatuximab is an innovative monoclonal antibody that has shown significant potential in treating various blood disorders, particularly multiple myeloma. This article delves into the ongoing clinical trials investigating the efficacy and safety of Isatuximab in different patient populations and treatment combinations. From newly diagnosed patients to those with relapsed or refractory disease, these trials aim to optimize treatment strategies and improve outcomes for individuals affected by multiple myeloma and related conditions.

Table of Contents

What is Isatuximab?

Isatuximab is a type of drug known as a monoclonal antibody. It is specifically designed to target a protein called CD38, which is found on the surface of certain blood cells, including cancerous plasma cells[6]. Isatuximab is also known by its brand name Sarclisa[2]. This medication has shown promising results in treating various blood disorders, particularly multiple myeloma.

How Isatuximab Works

Isatuximab works by binding to the CD38 protein on the surface of cancerous plasma cells. This binding triggers the body’s immune system to attack and destroy these cells[6]. By targeting CD38, Isatuximab can help reduce the number of cancerous cells in the body, potentially slowing down or stopping the progression of diseases like multiple myeloma.

Conditions Treated with Isatuximab

Isatuximab is primarily used to treat the following conditions:

  • Multiple Myeloma: This is the main condition for which Isatuximab is used. Multiple myeloma is a type of blood cancer that affects plasma cells, a type of white blood cell that produces antibodies[1].
  • Monoclonal Gammopathy of Renal Significance (MGRS): This is a condition where abnormal proteins produced by plasma cells can damage the kidneys[2].
  • AL Amyloidosis: This is a rare disease caused by the buildup of abnormal proteins in various organs, leading to organ dysfunction[7].
  • T-cell Acute Lymphoblastic Leukemia (T-ALL): This is a type of blood cancer that affects T-cells, a type of white blood cell[1].
  • Cryoglobulinemia: This is a condition where abnormal proteins in the blood thicken in cold temperatures, potentially causing circulation problems[4].

How Isatuximab is Administered

Isatuximab is typically administered in two ways:

  1. Intravenous (IV) Infusion: The drug is given directly into a vein. The dosage is usually based on the patient’s weight, often around 10 mg/kg[3].
  2. Subcutaneous Injection: Some trials are exploring the use of Isatuximab as a subcutaneous injection, which means it’s injected just under the skin[8].

The frequency of administration can vary depending on the treatment plan. It’s often given weekly for the first few weeks, then every two weeks thereafter[3].

Isatuximab in Combination Therapies

Isatuximab is often used in combination with other drugs to enhance its effectiveness. Common combinations include:

  • Isatuximab with Pomalidomide and Dexamethasone[7]
  • Isatuximab with Lenalidomide and Dexamethasone[5]
  • Isatuximab with Bortezomib and Dexamethasone[8]

These combinations have shown improved outcomes in treating multiple myeloma compared to single-drug treatments.

Current Clinical Trials

Several clinical trials are currently underway to further investigate the effectiveness of Isatuximab in various conditions and treatment scenarios. Some notable trials include:

  • Using Isatuximab in combination with standard chemotherapy for T-cell Acute Lymphoblastic Leukemia[1]
  • Evaluating Isatuximab for treating Monoclonal Gammopathy of Renal Significance[2]
  • Studying Isatuximab as a maintenance therapy after stem cell transplantation in multiple myeloma patients[5]
  • Investigating Isatuximab for treating type I cryoglobulinemia[4]

Potential Side Effects

Like all medications, Isatuximab can cause side effects. Common side effects may include:

  • Infusion-related reactions
  • Fatigue
  • Nausea
  • Decreased blood cell counts
  • Increased risk of infections

It’s important to discuss potential side effects with your healthcare provider[6].

Future Prospects

Isatuximab shows promise in treating various blood disorders, particularly multiple myeloma. Ongoing research is exploring its potential in other conditions and in combination with different therapies. As more clinical trials are completed, we may see expanded uses for this medication in the future[8][4].

Aspect Details
Main Conditions Studied Multiple myeloma, AL amyloidosis, MGRS, T-ALL, Cryoglobulinemia
Administration Methods Intravenous (most common), Subcutaneous (being investigated)
Common Dosage 10 mg/kg, frequency varies (often weekly in first cycle, then biweekly)
Combination Therapies Lenalidomide, Pomalidomide, Bortezomib, Dexamethasone
Primary Outcomes Measured Overall response rate, Progression-free survival, MRD negativity
Secondary Outcomes Safety, Quality of life, Duration of response, Overall survival
Patient Populations Newly diagnosed, Relapsed/Refractory, Post-transplant
Notable Trial Designs Phase II and III studies, including randomized and non-inferiority trials

FAQ

  • What is Isatuximab and how does it work? Isatuximab is a monoclonal antibody that targets CD38, a protein found on the surface of multiple myeloma cells. It works by binding to CD38 and triggering the immune system to attack and destroy cancer cells. Isatuximab also has direct anti-tumor effects and can interfere with the growth and survival of myeloma cells.
  • In which conditions is Isatuximab being studied? Isatuximab is primarily being studied in multiple myeloma, but clinical trials are also exploring its use in other conditions such as AL amyloidosis, monoclonal gammopathy of renal significance (MGRS), T-cell acute lymphoblastic leukemia (T-ALL), and cryoglobulinemic vasculitis.
  • How is Isatuximab administered in clinical trials? In most trials, Isatuximab is administered intravenously, typically at a dose of 10 mg/kg. Some studies are investigating subcutaneous administration. The frequency of administration varies, but it's often given weekly during the first cycle and then biweekly in subsequent cycles.
  • What are the common combination therapies used with Isatuximab? Isatuximab is frequently studied in combination with other drugs. Common combinations include Isatuximab with lenalidomide and dexamethasone, or with pomalidomide and dexamethasone. Some trials also combine it with bortezomib and dexamethasone.
  • What are the primary outcomes being measured in Isatuximab clinical trials? The primary outcomes often include overall response rate (ORR), progression-free survival (PFS), and minimal residual disease (MRD) negativity. Safety and tolerability are also key outcomes, with researchers monitoring for adverse events and changes in quality of life measures.

Ongoing Clinical Trials on Isatuximab

  • Study on Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Low-Risk Multiple Myeloma

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Germany

  • Study on Isatuximab, Bortezomib, and Lenalidomide for Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Denmark Norway

  • Study of isatuximab and pegenzileukin combination treatment for patients with relapsed or refractory multiple myeloma who previously received anti-CD38 and anti-BCMA therapy

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Greece Italy Norway Portugal

  • Study of Isatuximab with Lenalidomide and Dexamethasone for Elderly Patients (70+) with Newly Diagnosed Multiple Myeloma

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Greece

  • Study of isatuximab, belantamab mafodotin and dexamethasone combination for patients with relapsed or refractory multiple myeloma

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Greece Italy Norway

  • Study Comparing Lenalidomide, Bortezomib, Dexamethasone, Isatuximab, and Iberdomide for Newly Diagnosed Multiple Myeloma Patients Eligible for Stem Cell Transplant

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. Isatuximab is a monoclonal antibody that targets CD38 on myeloma cells.
  • Multiple myeloma: A type of blood cancer that affects plasma cells, which are a type of white blood cell that normally produces antibodies to fight infections.
  • CD38: A protein found on the surface of multiple myeloma cells and other immune cells. It is the target of Isatuximab.
  • Overall response rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Minimal residual disease (MRD): A small number of cancer cells that remain in the body during or after treatment. Being MRD-negative means no cancer cells are detected using highly sensitive tests.
  • Autologous stem cell transplantation (ASCT): A procedure where a patient's own stem cells are collected, stored, and then given back after high-dose chemotherapy to help restore the bone marrow.
  • Refractory: Describing a disease or condition that does not respond to treatment.
  • AL amyloidosis: A rare disease caused by the buildup of abnormal protein fibers (amyloid) in various organs, often associated with plasma cell disorders.
  • Cryoglobulinemia: A condition where abnormal proteins in the blood clump together in cold temperatures, potentially causing inflammation of blood vessels.
  • Monoclonal gammopathy of renal significance (MGRS): A condition where an abnormal protein produced by plasma cells causes kidney damage.
  • T-cell acute lymphoblastic leukemia (T-ALL): A type of blood cancer that affects T-lymphocytes, a type of white blood cell.

References